{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:52:41Z","timestamp":1788306761450,"version":"build-2803163510"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T00:00:00Z","timestamp":1689120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Therapeutic strategies for patients with ulcerative colitis (UC) are based on patient- and disease-related factors in combination with drug characteristics but fail to predict success in individual patients. A considerable proportion of UC patients do not respond to the biological vedolizumab. Therefore, pretreatment biomarkers for therapeutic efficacy are urgently needed. Mucosal markers related to the integrin-dependent T lymphocyte homing could be potent predictors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We prospectively included 21 biological- and steroid-naive UC patients with moderate-to-severe disease activity planned to escalate therapy to vedolizumab. At week 0, before initiating treatment, colonic biopsy specimens were obtained for immunophenotyping and immunohistochemistry. Clinical and endoscopic disease activity were determined at week 16 after 4 infusions of vedolizumab. In addition, we retrospectively included 5 UC patients who were first treated with anti-tumor necrosis factor \u03b1 before receiving vedolizumab to compare with biological-naive patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Abundance of \u03b14\u03b27 on more than 8% of all CD3+ T lymphocytes in colonic biopsies at baseline was predictive for responsiveness to vedolizumab (sensitivity 100%, specificity 100%). The threshold for the proportion of MAdCAM-1+ and PNAd+ of all venules in the biopsies predictive for responsiveness to vedolizumab was \u22652.59% (sensitivity 89%, specificity 100%) and \u22652.41% (sensitivity 61%, specificity 50%), respectively. At week 16, a significant decrease of \u03b14\u03b27+CD3+T lymphocytes was demonstrated in responders (18% [12%-24%] to 8% [3%-9%]; P\u2005=\u2005.002), while no difference was seen in nonresponders (4% [3%-6%] to 3%; P\u2005= .59).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>UC responders to vedolizumab have a higher percentage of \u03b14\u03b27+CD3+ T lymphocytes and a higher proportion of MAdCAM-1+ venules in colonic biopsies than nonresponders before initiating therapy. Both analyses could be promising predictive biomarkers for therapeutic response and may lead to more patient tailored treatment in the future.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ibd\/izad123","type":"journal-article","created":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T16:43:18Z","timestamp":1689180198000},"page":"930-938","source":"Crossref","is-referenced-by-count":5,"title":["Mucosal \u03b14\u03b27+ Lymphocytes and MAdCAM+ Venules Predict Response to Vedolizumab in Ulcerative Colitis"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7249-6840","authenticated-orcid":false,"given":"Britt","family":"Roosenboom","sequence":"first","affiliation":[{"name":"Crohn & Colitis Centre Rijnstate, Department of Gastroenterology and Hepatology, Rijnstate Hospital , Arnhem , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J","family":"Wahab","sequence":"additional","affiliation":[{"name":"Crohn & Colitis Centre Rijnstate, Department of Gastroenterology and Hepatology, Rijnstate Hospital , Arnhem , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolijn","family":"Smids","sequence":"additional","affiliation":[{"name":"Crohn & Colitis Centre Rijnstate, Department of Gastroenterology and Hepatology, Rijnstate Hospital , Arnhem , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos","family":"Meijer","sequence":"additional","affiliation":[{"name":"Department of Pathology, Rijnstate Hospital , Arnhem , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa G J M","family":"Kemperman","sequence":"additional","affiliation":[{"name":"Department of Pathology, Rijnstate Hospital , Arnhem , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel J M","family":"Groenen","sequence":"additional","affiliation":[{"name":"Crohn & Colitis Centre Rijnstate, Department of Gastroenterology and Hepatology, Rijnstate Hospital , Arnhem , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen G","family":"van Lochem","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Rijnstate Hospital , Arnhem , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen S","family":"Horjus Talabur Horje","sequence":"additional","affiliation":[{"name":"Crohn & Colitis Centre Rijnstate, Department of Gastroenterology and Hepatology, Rijnstate Hospital , Arnhem , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,7,12]]},"reference":[{"issue":"8","key":"2024060305532190100_CIT0001","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1080\/17474124.2018.1494573","article-title":"How to predict response to anti-tumour necrosis factor agents in inflammatory bowel disease","volume":"12","author":"Naviglio","year":"2018","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"5","key":"2024060305532190100_CIT0002","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","article-title":"The safety of vedolizumab for ulcerative colitis and Crohn\u2019s disease","volume":"66","author":"Colombel","year":"2017","journal-title":"Gut."},{"issue":"8","key":"2024060305532190100_CIT0003","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med."},{"key":"2024060305532190100_CIT0004","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3389\/fmed.2020.00076","article-title":"Predicting response to vedolizumab in inflammatory bowel disease","volume":"7","author":"Meserve","year":"2020","journal-title":"Front Med"},{"issue":"11","key":"2024060305532190100_CIT0005","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1093\/ibd\/izy171","article-title":"Predictors and management of loss of response to vedolizumab in inflammatory bowel disease","volume":"24","author":"Shmidt","year":"2018","journal-title":"Inflamm Bowel Dis."},{"issue":"1","key":"2024060305532190100_CIT0006","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41575-019-0228-5","article-title":"Interrogating host immunity to predict treatment response in inflammatory bowel disease","volume":"17","author":"Digby-Bell","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol."},{"issue":"4","key":"2024060305532190100_CIT0007","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1093\/ecco-jcc\/jjx160","article-title":"Intestinal T cell profiling in inflammatory bowel disease: Linking T cell subsets to disease activity and disease course","volume":"12","author":"Smids","year":"2018","journal-title":"J Crohns Colitis"},{"issue":"4","key":"2024060305532190100_CIT0008","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1097\/MIB.0000000000001067","article-title":"Novel insights into the mechanisms of gut homing and antiadhesion therapies in inflammatory bowel diseases","volume":"23","author":"Zundler","year":"2017","journal-title":"Inflamm Bowel Dis."},{"issue":"3","key":"2024060305532190100_CIT0009","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/0016-5085(94)90691-2","article-title":"Aberrant binding of lamina propria lymphocytes to vascular endothelium in inflammatory bowel diseases","volume":"106","author":"Salmi","year":"1994","journal-title":"Gastroenterology."},{"issue":"9","key":"2024060305532190100_CIT0010","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1136\/gutjnl-2018-317977","article-title":"Immune cell trafficking and retention in inflammatory bowel disease: mechanistic insights and therapeutic advances","volume":"68","author":"Zundler","year":"2019","journal-title":"Gut."},{"issue":"6","key":"2024060305532190100_CIT0011","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/ecco-jcc\/jjx008","article-title":"Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders","volume":"11","author":"Magro","year":"2017","journal-title":"J Crohns Colitis"},{"key":"2024060305532190100_CIT0012","doi-asserted-by":"crossref","first-page":"5A","DOI":"10.1155\/2005\/269076","article-title":"Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World congress of gastroenterology","volume":"Suppl A","author":"Silverberg","year":"2005;19","journal-title":"Can J Gastroenterol."},{"issue":"7","key":"2024060305532190100_CIT0013","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/apt.14550","article-title":"Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease","volume":"47","author":"Barre","year":"2018","journal-title":"Aliment Pharmacol Ther."},{"issue":"11","key":"2024060305532190100_CIT0014","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1016\/j.cgh.2016.02.016","article-title":"Effectiveness and safety of vedolizumab induction therapy for patients with inflammatory bowel disease","volume":"14","author":"Amiot","year":"2016","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"1","key":"2024060305532190100_CIT0015","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/MIB.0000000000000979","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease in patients naive to or who have failed tumor necrosis factor antagonist therapy","volume":"23","author":"Sands","year":"2017","journal-title":"Inflamm Bowel Dis."},{"issue":"8","key":"2024060305532190100_CIT0016","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1093\/ecco-jcc\/jjz041","article-title":"Higher trough vedolizumab concentrations during maintenance therapy are associated with corticosteroid-free remission in inflammatory bowel disease","volume":"13","author":"Ungaro","year":"2019","journal-title":"J Crohns Colitis"},{"issue":"11","key":"2024060305532190100_CIT0017","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s40262-017-0546-0","article-title":"A review of the clinical pharmacokinetics, pharmacodynamics, and immunogenicity of vedolizumab","volume":"56","author":"Rosario","year":"2017","journal-title":"Clin Pharmacokinet."},{"issue":"2","key":"2024060305532190100_CIT0018","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1093\/ibd\/izy307","article-title":"Biomarkers are associated with clinical and endoscopic outcomes with vedolizumab treatment in ulcerative colitis","volume":"25","author":"Battat","year":"2019","journal-title":"Inflamm Bowel Dis."},{"key":"2024060305532190100_CIT0019","doi-asserted-by":"crossref","first-page":"764","DOI":"10.3389\/fimmu.2017.00764","article-title":"Clinical response to vedolizumab in ulcerative colitis patients is associated with changes in integrin expression profiles","volume":"8","author":"Fuchs","year":"2017","journal-title":"Front Immunol."},{"issue":"9","key":"2024060305532190100_CIT0020","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1007\/s10620-018-4924-8","article-title":"Identification of candidate biomarkers associated with response to vedolizumab in inflammatory bowel disease","volume":"63","author":"Boden","year":"2018","journal-title":"Dig Dis Sci."},{"issue":"8","key":"2024060305532190100_CIT0021","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.3390\/ijms18081827","article-title":"Systemic chemokine levels with \u201cgut-specific\u201d vedolizumab in patients with inflammatory bowel disease-A pilot study","volume":"18","author":"Zwicker","year":"2017","journal-title":"Int J Mol Sci ."},{"issue":"6","key":"2024060305532190100_CIT0022","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s10787-013-0177-5","article-title":"The multiple faces of CCL13 in immunity and inflammation","volume":"21","author":"Mendez-Enriquez","year":"2013","journal-title":"Inflammopharmacology"},{"issue":"1","key":"2024060305532190100_CIT0023","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s12876-020-01253-8","article-title":"Baseline levels of dynamic CD4+ T cell adhesion to MAdCAM-1 correlate with clinical response to vedolizumab treatment in ulcerative colitis: a cohort study","volume":"20","author":"Allner","year":"2020","journal-title":"BMC Gastroenterol."},{"key":"2024060305532190100_CIT0024","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.3389\/fimmu.2018.01700","article-title":"Effects of anti-integrin treatment with vedolizumab on immune pathways and cytokines in inflammatory bowel disease","volume":"9","author":"Rath","year":"2018","journal-title":"Front Immunol."},{"issue":"4","key":"2024060305532190100_CIT0025","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.4049\/jimmunol.174.4.2343","article-title":"L-selectin, alpha 4 beta 1, and alpha 4 beta 7 integrins participate in CD4+ T cell recruitment to chronically inflamed small intestine","volume":"174","author":"Rivera-Nieves","year":"2005","journal-title":"J Immunol."},{"issue":"3","key":"2024060305532190100_CIT0026","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/MIB.0000000000001029","article-title":"The a4b1 homing pathway is essential for ileal homing of Crohn\u2019s disease effector T cells in vivo","volume":"23","author":"Zundler","year":"2017","journal-title":"Inflamm Bowel Dis."},{"issue":"5","key":"2024060305532190100_CIT0027","first-page":"678","article-title":"Alterations in MAdCAM1-positive mucosal capillaries and integrin a4b7-positive lymphocytes in Crohn\u2019s disease treated with anti-TNF\u03b1 biologics","volume":"51","author":"Younes","year":"2021","journal-title":"Ann Clin Lab Sci."},{"issue":"4","key":"2024060305532190100_CIT0028","doi-asserted-by":"crossref","first-page":"891","DOI":"10.3390\/cells9040891","article-title":"Development of mucosal PNAd+ and MAdCAM-1+ venules during disease course in ulcerative colitis","volume":"9","author":"Roosenboom","year":"2020","journal-title":"Cells"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izad123\/50864306\/izad123.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/30\/6\/930\/57800091\/izad123.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/30\/6\/930\/57800091\/izad123.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T14:34:57Z","timestamp":1717425297000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/30\/6\/930\/7223328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,12]]},"references-count":28,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,7,12]]},"published-print":{"date-parts":[[2024,6,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izad123","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,6,1]]},"published":{"date-parts":[[2023,7,12]]}}}